Merck & Co., Inc. (VIE:MRK)

Market Cap	236.43B
Revenue (ttm)	54.75B
Net Income (ttm)	16.22B
Shares Out	n/a
EPS (ttm)	6.44
PE Ratio	14.57
Forward PE	13.29
Dividend	2.86 (3.07%)
Ex-Dividend Date	Dec 15, 2025

Volume	8
Average Volume	112
Open	92.70
Previous Close	93.20
Day's Range	92.70 - 93.90
52-Week Range	66.10 - 99.10
Beta	0.30
RSI	66.56
Earnings Date	Feb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: MRK

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD